EnGeneIC Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Later Stage VC
  • (Cancelled)

  • Latest Deal Amount
  • $25M

  • Investors
  • 5

EnGeneIC General Information

Description

Developer of a clinical-stage biopharmaceutical company designed to target the delivery of chemotherapeutics and functional nucleic acids in cancer. The company's Cyto-immunotherapy technology utilizes antibody-targeted, bacterial-derived, non-living nano cells to release high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into targeted tumor cells, helping patients with cancer treatments that are potent and less toxic, while also offering a potential new means for treating drug-resistant cancers.

Contact Information

Website
www.engeneic.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Level 4, Building 53
  • 11 Julius Avenue, North Ryde
  • Sydney, New South Wales 2113
  • Australia
+61 (02)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Level 4, Building 53
  • 11 Julius Avenue, North Ryde
  • Sydney, New South Wales 2113
  • Australia
+61 (02)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EnGeneIC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 20-Nov-2021 $25M Cancelled Clinical Trials - Phase 2
7. IPO 22-Nov-2021 Cancelled Clinical Trials - Phase 2
6. Equity Crowdfunding 20-Nov-2021 Completed Clinical Trials - Phase 2
5. Later Stage VC 13-Apr-2017 Completed Clinical Trials - Phase 2
4. Later Stage VC 24-Jul-2015 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 06-Jan-2015 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 30-Apr-2014 $44.6M $45.6M Completed Generating Revenue
1. Seed Round 27-Jul-2011 $1.02M $1.02M Completed Startup
To view EnGeneIC’s complete valuation and funding history, request access »

EnGeneIC Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A
To view EnGeneIC’s complete cap table history, request access »

EnGeneIC Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a clinical-stage biopharmaceutical company designed to target the delivery of chemotherapeutics and functio
Drug Discovery
Sydney, Australia
29 As of 2024

Cambridge, MA
 

Toowong, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EnGeneIC Competitors (28)

One of EnGeneIC’s 28 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Kira Biotech Venture Capital-Backed Toowong, Australia
Carina Biotech Venture Capital-Backed Mawson Lakes, Australia
Genentech Formerly VC-backed South San Francisco, CA
MedinCell Formerly VC-backed Jacou, France
You’re viewing 5 of 28 competitors. Get the full list »

EnGeneIC Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EnGeneIC Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
VentureCrowd Other Minority
CHAMP Ventures PE/Buyout Minority
Foley Ventures Venture Capital Minority
Momentum Investment Group Venture Capital Minority
Shepherd Kaplan Krochuk Asset Manager Minority
To view EnGeneIC’s complete investors history, request access »

Ready to get started?

Request a free trial

EnGeneIC FAQs

  • When was EnGeneIC founded?

    EnGeneIC was founded in 2001.

  • Where is EnGeneIC headquartered?

    EnGeneIC is headquartered in Sydney, Australia.

  • What is the size of EnGeneIC?

    EnGeneIC has 29 total employees.

  • What industry is EnGeneIC in?

    EnGeneIC’s primary industry is Drug Discovery.

  • Is EnGeneIC a private or public company?

    EnGeneIC is a Private company.

  • What is EnGeneIC’s current revenue?

    The current revenue for EnGeneIC is .

  • How much funding has EnGeneIC raised over time?

    EnGeneIC has raised $63.7M.

  • Who are EnGeneIC’s investors?

    VentureCrowd, CHAMP Ventures, Foley Ventures, Momentum Investment Group, and Shepherd Kaplan Krochuk have invested in EnGeneIC.

  • Who are EnGeneIC’s competitors?

    Alnylam Pharmaceuticals, Kira Biotech, Carina Biotech, Genentech, and MedinCell are some of the 28 competitors of EnGeneIC.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »